skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
Bcr-Abl (b3a2)-Derived Peptide Vaccine (Code C61310)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Bcr-Abl (b3a2)-Derived Peptide Vaccine

Definition: A peptide vaccine consisting of the bcr-abl b3a2 fusion oncoprotein, frequently expressed in chronic myelogenous leukemia (CML), with potential antineoplastic activity. Vaccination with the bcr-abl (b3a2)-derived peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells that express the bcr-abl b3a2 fusion protein. Fusion genes in CML typically result from the fusion of either BCR exon b2 or BCR exon b3 to ABL exon a2, a 'b3a2' or a 'b2a2' fusion.

Display Name: Bcr-Abl (b3a2)-Derived Peptide Vaccine

Label: Bcr-Abl (b3a2)-Derived Peptide Vaccine

NCI Thesaurus Code: C61310 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C1831814  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Bcr-Abl (b3a2)-Derived Peptide Vaccine

External Source Codes: 
PDQ Closed Trial Search ID 484893
PDQ Open Trial Search ID 484893 (check for NCI PDQ open clinical trial info)
UMLS CUI C1831814

Other Properties:
     Name Value (qualifiers indented underneath)
code C61310
Contributing_Source CTRP
Legacy_Concept_Name Bcr-Abl_b3a2_Derived_Peptide_Vaccine
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom